Windlas Biotech Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/8g4fchfdltvrwc8u7oob9bcw.pdf

Key Takeaways


CDMO & Trade Generics Momentum

Hitesh Windlass: "So, my sense is that in the long run, this will definitely have a positive impact. More demand will be there. And for us, as a business, we will also reap the benefit of that."

Injectables: The Next Growth Leg

Komal Gupta: "Injectables definitely is a higher margin business for us. Then once we reach the peak level, we expect EBITDA margins like 17%, 18% in our injectable business."

Export Vertical: Small Base, Big Ambition

Hitesh Windlass: "we do not have any feet on the ground in any of these markets."

Margins & Operating Leverage

Hitesh Windlass: "the regulators who come to speak have very clearly spoken and said that those companies who are not implementing Schedule M, in letter and spirit, will be weeded out."

Balance Sheet & Working Capital

Komal Gupta: "Pre-IPO level is the general level. So 30 days, 40 days is a good number that we gun for."

Guidance & Commitments

CommitmentSpecificsTimeline
Injectables revenue commencementRevenue generation from injectables facility to beginNext fiscal year (FY25)
Injectables peak EBITDA margin17-18% EBITDA margin at peak utilizationAt peak level (no date)
Working capital target30-40 daysSustained, no reversion to post-IPO highs
New facility capex~INR40 crores total for INR1,000 crore turnover capacity; INR20 crores initialPhased as need increases
Dossier-to-revenue cycle6-12 months to file, 18-24 months for approval, then commercializationMulti-year from filing start

Key Metrics

MetricQ2 FY24
Revenue₹153 cr, +15% YoY
EBITDA₹19 cr, +17% YoY
PAT₹14 cr, +15% YoY
EPS₹6.75
H1 FY24 EPS₹12.54, +24% YoY, highest since listing
H1 operating cash flow₹54 cr
Liquidity position₹167 cr at quarter end
CDMO vertical revenue₹117.8 cr, +10% YoY
Trade generics & institutional revenue₹28.3 cr, +23% YoY
Export vertical revenue₹6.4 cr, +157% YoY
Capacity utilization~55%
Working capital days33 days at quarter end
Injectable facility capex~₹70 cr